Panomics Relationships in the Epidemiology of Cancer Through In Silico Expression (PRECISE)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- Greater Baltimore Medical Center
- Locations
- 1
- Primary Endpoint
- Panomics Relationships in the Epidemiology of Cancer through In Silico Expression (PRECISE)
- Status
- Withdrawn
- Last Updated
- 5 years ago
Overview
Brief Summary
PRECISE is a study to discover new detection, prognosis and treatment biomarkers for cancer. This is a prospective, multi-center, observational study designed to collect de-identified biospecimens and clinical data from a large cohort of participants from clinical research networks in the United States. In this study, the investigators propose creating a large-scale normalized panomics dataset specifically designed for deep learning-based in silico analysis for biomarker discovery.
Detailed Description
This study will enroll all subjects who are eligible and willing to participate with a goal of enrolling at least 10,000 in several categories: (i) Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, and (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Family History of Cancer
- •Ages 18 or older
- •Either of the following:
- •Patients with two or more first, second or third degree blood relatives on the same side of the family diagnosed with cancer
- •Patients with one or more first, second or third degree blood relative with male breast cancer
- •Patients with a first, second, or third degree blood relative with a known BRCA1 or BRCA2 mutation
- •Patients with a first, second, or third degree blood relative who has had colorectal or endometrial cancer diagnosed before age 50 years
- •Patients with first degree relatives with a known deleterious APC, MEN1, MUTYH, PTEN, RET, STK11, TP53, or VHL gene mutation
- •Patients of Ashkenazi Jewish descent with one or more first degree relatives or two or more second degree relatives with breast, ovarian or colorectal cancer
- •The patient has signed the appropriate Institutional Review Board approved Informed Consent Form
Exclusion Criteria
- •Blood or blood product transfusion in the preceding 2 months
- •Cognitive impairment as determined by clinical history
- •Pregnant women (by self-report of pregnancy status)
- •Inability to speak English
- •Previous diagnosis of cancer except: non-melanomatous skin cancer
- •Poor health status or unfit to tolerate blood draw
Outcomes
Primary Outcomes
Panomics Relationships in the Epidemiology of Cancer through In Silico Expression (PRECISE)
Time Frame: 5 years
● Discover and validate new detection, prognosis and treatment biomarkers for cancer